Synthesis and characterization of organic impurities in bortezomib anhydride produced by a convergent technology

Scientia Pharmaceutica

Volumn 80, Issue 1, 2012, Pages 67-75

  Ivanov, Andrey S ^a   Shishkov, Sergey V ^a   Zhalnina, Anna A ^a  

^a F Synthesis LLC   (Russian Federation)

Author keywords

Bortezomib; Chemical synthesis; Chirality; HPLC; Impurities; Mass spectrometry; Oxidation; Velcade

Indexed keywords

BORON; BORTEZOMIB; DEXTRO PHENYLALANINE; HYDROXYL GROUP; PHENYLALANINE;

ARTICLE; CHIRALITY; DRUG DEGRADATION; DRUG IMPURITY; DRUG SYNTHESIS; DRUG TRANSFORMATION; EPIMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; OXIDATION; RACEMIZATION;

EID: 84857927571     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1109-02     Document Type: Article

References (12)

1. Bross PF, Kane R, Farrell AT, Abraham S, Benson K, Brower ME, Bradley S, Gobburu JV, Goheer A, Lee S-L, Leighton J, Liang CY, Lostritto RT, McGuinn WD, Morse DE, Rahman A, Rosario LA, Verbois SL, Williams G, Wang Y-C, Pazdur R. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res. 2004; 10: 3954-3964. http://dx.doi.org/10.1158/1078-0432.CCR-03-0781
2. Bonvini P, Zorzi E, Basso G, Rosolen A. Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia. 2007; 21: 838-842. http://dx.doi.org/10.1038/sj.leu.2404528
3. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001; 8: 739-758. http://dx.doi.org/10.1016/S1074-5521(01)00056-4
4. Adams J. Proteasome Inhibitors in Cancer Therapy. Humana Press, Totowa, 2004.
5. Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure. 2006; 14: 451-456. http://dx.doi.org/10.1016/j.str.2005.11.019
6. Troy DB, Beringer P. Remington: the science and practice of pharmacy. 21st Ed., Philadelphia, PA. Lippincott Williams & Wilkins, 2005.
7. Bolognese A, Esposito A, Manfra M, Catalano L, Petruzziello F, Martorelli MC, Pagliuca R, Mazzarelli V, Ottiero M, Scalfaro M, Rotoli B. An NMR study of the bortezomib degradation under clinical use conditions. Adv Hematol. 2009; 1-5. http://dx.doi.org/10.1155/2009/704928
8. Wu S, Waugh W, Stella VJ. Degradation pathways of a peptide boronic acid derivative, 2-Pyz-(CO)-Phe-Leu-B(OH)2. J Pharm Sci. 2000; 89: 758-765. http://dx.doi.org/10.1002/(SICI)1520-6017(200006)89:6758::AID-JPS73.0.CO;2-L
9. Ivanov AS, Zhalnina AA, Shishkov SV. A convergent approach to synthesis of bortezomib: the use of TBTU suppresses racemization in the fragment condensation. Tetrahedron. 2009; 65: 7105-7108. http://dx.doi.org/10.1016/j.tet.2009.06.042
10. ICH Guideline Q3A (R2). Impurities in new drug substances, 25 October 2006
11. Barrett GC, Elmore DT. Amino acids and peptides. Cambridge University Press: Cambridge, 1998.
12. Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, Hsieh F, Gan L-S, Miwa G. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metabol Disp. 2005; 33: 771-777. http://dx.doi.org/10.1124/dmd.104.002956